Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biotechnol Lett ; 35(2): 175-80, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23086571

ABSTRACT

Current methods to monitor cellular ATP do not provide spatial or temporal localization of ATP in single cells in real time or they display imperfect specificity to ATP. Here, we have developed a single cell, Enhanced Acceptor Fluorescence (EAF)-based ATP biosensor to visualize ATP in real time. This biosensor utilizes a modified mimic of the ε-subunits of the Bacillus subtilis F(0)F(1) synthase and is coupled to the EAF fluorophores pairs, GFP and YFP. The sensor was then used to monitor ATP in a heterogeneous glioblastoma multiform cancer cell population. We anticipate that this innovative technology and our better understanding of the ATP machinery will have substantial influence on future translational studies.


Subject(s)
Adenosine Triphosphate/analysis , Biosensing Techniques/methods , Cytological Techniques/methods , Glioblastoma/physiopathology , Bacillus subtilis/enzymology , Fluorescence , Humans , Proton-Translocating ATPases/metabolism
2.
Appl Microbiol Biotechnol ; 96(4): 895-902, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23053099

ABSTRACT

Förster (or fluorescence) resonance energy transfer (FRET) is a process involving the radiation-less transfer of energy from a "donor" fluorophore to an "acceptor" fluorophore. FRET technology enables the quantitative analysis of molecular dynamics in biophysics and in molecular biology, such as the monitoring of protein-protein interactions, protein-DNA interactions, and protein conformational changes. FRET-based biosensors have been utilized to monitor cellular dynamics not only in heterogeneous cellular populations, but also at the single-cell level in real time. Lately, applications of FRET-based biosensors range from basic biological to biomedical disciplines. Despite the diverse applications of FRET, FRET-based sensors still face many challenges. There is an increasing need for higher fluorescence resolution and improved specificity of FRET biosensors. Additionally, as more FRET-based technologies extend to medical diagnostics, the affordability of FRET reagents becomes a significant concern. Here, we will review current advances and limitations of FRET-based biosensor technology and discuss future FRET applications.


Subject(s)
Biosensing Techniques/trends , Cells/chemistry , Energy Metabolism , Fluorescence Resonance Energy Transfer/trends , Animals , Biosensing Techniques/instrumentation , Biosensing Techniques/methods , Cells/cytology , Cells/metabolism , Fluorescence Resonance Energy Transfer/instrumentation , Fluorescence Resonance Energy Transfer/methods , Humans , Proteins/genetics , Proteins/metabolism
3.
Tumour Biol ; 33(6): 2411-21, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22992974

ABSTRACT

Gliomablastoma multiforme (GBM) is the most aggressive of brain cancers in humans. Response to current therapies remains extremely poor, with dismal survival statistics. Recently, the endoplasmic reticulum UDPase, ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), was identified as a key component in the Akt/phosphatidylinositol 3-kinase/phosphatase and tensin homolog regulatory loop, capable of synergizing aerobic glycolysis and cancer cell proliferation in vitro. Utilizing a novel enhanced acceptor fluorescence-based single-cell adenosine 5'-triphosphate (ATP) biosensor, we analyzed ENTPD5-mediated modulation of cytosolic ATP. Here, ENTPD5-dependent modulation of cellular ATP in GBM results in altered metabolic kinetics in vitro, increasing the catabolic efficiencies of aerobic glycolysis and fatty acid oxidation. Additionally, an upregulation of ENTPD5 in both GBM mouse xenografts and in GBM patient tumors was identified, resulting in dramatically reduced survival. Therefore, these results not only provide new tools to monitor ATP flux and cellular metabolism kinetics but also identified a novel therapeutic target for GBM.


Subject(s)
Adenosine Triphosphate/metabolism , Brain Neoplasms/mortality , Brain/metabolism , Glioblastoma/mortality , Lipid Metabolism , Oncogene Proteins/metabolism , Oxygen Consumption , Pyrophosphatases/metabolism , Animals , Autophagy , Blotting, Western , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Proliferation , Glioblastoma/metabolism , Glioblastoma/pathology , Glucose/metabolism , Glycolysis , Humans , Immunoenzyme Techniques , Lactic Acid/metabolism , Mice , Nanoparticles , Oncogene Proteins/antagonists & inhibitors , Oncogene Proteins/genetics , Prognosis , Pyrophosphatases/antagonists & inhibitors , Pyrophosphatases/genetics , RNA, Small Interfering/genetics , Survival Rate , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...